A growth-hormone-releasing factor analogue studied in HIV-associated abdominal fat accumulation.
In simple words
Tesamorelin is a peptide modelled on a signal that stimulates growth-hormone release. The selected clinical research concerns abdominal fat accumulation in people living with HIV, not general fitness outcomes.
The named research compound is described here; the identity and formulation of this catalogue vial have not been independently verified.
404 people with HIV and excess abdominal fat in the context of antiretroviral treatment.
The growth-hormone-releasing factor analogue reduced visceral fat in the studied population and increased IGF-I.
Benefits were lost after switching to placebo. A specific clinical population cannot establish general fat-loss benefits. Although tolerability was reported, long-term safety and this vial are not established.
PMID 20101189. Indexed abstract checked through Europe PMC on 2026-10-26. Selected evidence, not a systematic review.
Resources
Compound name and formula checked via PubChem PUG REST. This reference does not verify the vial, salt or formulation.
Evidence on studied compounds does not establish the identity, purity, safety, or regulatory approval of the catalogue vial. No Canadian regulatory status is assessed here.
Research questions about Tesamorelin
What is Tesamorelin?
Tesamorelin is a peptide modelled on a signal that stimulates growth-hormone release. The selected clinical research concerns abdominal fat accumulation in people living with HIV, not general fitness outcomes.
What types of research are cited for Tesamorelin?
The Tesamorelin profile contains the following selected evidence. This is not a systematic review or a complete inventory of research.
Tesamorelin and visceral fat in HIV (2010): Human — randomized trial with extension
The named research compound is described here; the identity and formulation of this catalogue vial have not been independently verified.
What do the selected Tesamorelin studies not establish?
Tesamorelin and visceral fat in HIV (2010): Benefits were lost after switching to placebo. A specific clinical population cannot establish general fat-loss benefits. Although tolerability was reported, long-term safety and this vial are not established.
These studies do not establish the identity, purity, safety or effects of the MXC Tesamorelin vial. Findings in one formulation, population or experimental model should not be assumed to apply to another.